[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:glioma:idh1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Glioma","IDH1 Gene",5,[8,16,23,30,37],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03922555","ASTX727 in Recurrent\u002FProgressive Non-enhancing IDH Mutant Gliomas",[12],"Phase 1","RECRUITING","2026-08-26T02:18:42.501841Z","2026-05-05T02:43:28.502498Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05303519","SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)",[20],"Phase 3","2026-08-26T02:18:51.009190Z","2026-05-05T02:43:27.742731Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[27],"Phase 1\u002FPhase 2","2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT07486713","Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies",[34],"Phase 4","2026-08-26T02:18:38.077159Z","2026-05-05T02:43:29.588444Z",{"nct_id":38,"title":39,"phases":40,"status":41,"updated_at":42,"content_modified":43},"NCT07219199","Residual IDH1-Mutant Tumor Cell Quantification Study",[],"NOT_YET_RECRUITING","2026-08-26T02:16:22.235886Z","2026-05-05T02:43:27.664599Z"]